| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 90.7 | 25.5 | 21.8 |
| Other income | 3.0 | 0.3 | 2.4 |
| Total income | 93.7 | 25.9 | 24.2 |
| Profit before exceptional items & tax | 3.5 | 0.6 | 0.6 |
| Profit before tax | 3.5 | 0.6 | 0.6 |
| Net profit | 2.6 | 0.4 | 0.2 |
| Operating margin | 3.7% | 2.3% | 2.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1200.00% |
|---|---|
| Net profit, quarter on quarter | +550.00% |
| Revenue, year on year | +316.10% |
BSE results filing, BSE: 542934. Figures extracted from the filing.
Chandra Bhagat Pharma Ltd: key numbers
- Share price
- ₹42.37
- Market cap
- ₹31.97 Cr
- Revenue (annual)
- ₹116.3 Cr
- Net profit (annual)
- ₹3.05 Cr
- P/E (TTM)
- 10.5×Sector 47.3×
- Promoter holding
- 73.02%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chandra Bhagat Pharma Ltd
All →Chandra Bhagat Pharma Annual General Meeting
Chandra Bhagat Pharma Limited conducted its 23rd Annual General Meeting on September 1, 2026, covering annual accounts, director reappointment, capital increase, and warrant issuance.
Chandra Bhagat Pharma Annual General Meeting
Chandra Bhagat Pharma Limited issued a corrigendum to its AGM notice regarding a proposed preferential issue. The update provides a web link to the required compliance certificate.
Chandra Bhagat Pharma Annual General Meeting
Chandra Bhagat Pharma Limited has issued a notice for its Annual General Meeting scheduled for September 1, 2026, to discuss financial and corporate resolutions.
Chandra Bhagat Pharma Annual Report
Chandra Bhagat Pharma Ltd has submitted its Annual Report for the financial year 2025-26 and notice for the 23rd Annual General Meeting.
Chandra Bhagat Pharma Fund Raise of ₹29.04 Cr
Chandra Bhagat Pharma Limited approved a preferential issue of 66 lakh convertible warrants worth Rs 29.04 crore and increased its authorized share capital.
- Value
- ₹29.04 Cr
Chandra Bhagat Pharma Board Meeting Date
Chandra Bhagat Pharma scheduled a board meeting for August 5, 2026. The agenda includes considering a fundraise via preferential allotment and increasing authorized share capital.